Valuation: Lundbeck

Market Cap 41.78B 6.41B 5.59B 5.26B 4.79B 8.99B 614B 9B 63.03B 24.29B 313B 24.08B 23.54B 1,009B P/E 2026 *
9.37x
P/E 2027 * 9.23x
Enterprise Value 45.78B 7.02B 6.12B 5.77B 5.25B 9.85B 673B 9.86B 69.07B 26.62B 343B 26.38B 25.8B 1,106B EV / Sales 2026 *
1.77x
EV / Sales 2027 * 1.6x
Free-Float
30.74%
Yield 2026 *
3.65%
Yield 2027 * 3.28%
1 day+4.39%
1 week-4.37%
Current month+0.98%
1 month+4.69%
3 months+2.71%
6 months+13.67%
Current year-1.39%
1 week 5.58
Extreme 5.575
5.74
1 month 5.48
Extreme 5.485
6.06
Current year 4.85
Extreme 4.852
6.26
1 year 4.85
Extreme 4.852
6.4
3 years 3.67
Extreme 3.666
6.62
5 years 3.26
Extreme 3.259
8.85
10 years 3.26
Extreme 3.259
8.85
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+4.39%-4.37% - - 6.41B
+1.40%-2.61%+27.28%+102.43% 102B
+0.14%-3.88%+53.10%+153.40% 52.42B
-0.78%-3.80%-16.23%+235.10% 20.85B
+1.19%-1.23%-10.26%-9.86% 7.88B
+2.53%+1.90%-35.75%-34.02% 6.83B
+4.09%-0.81%-1.34%+18.51% 6.41B
+0.60%-1.63%-17.84%-33.29% 5.97B
+1.10%-1.08%-2.94%+19.13% 4.94B
-2.92%+0.71%+12.05%+10.49% 3.79B
Average +1.21%-1.51%+0.90%+51.32% 23.45B
Weighted average by Cap. +0.99%-1.82%+22.83%+109.60%

Financials

2026 *2027 *
Net sales 25.91B 3.97B 3.47B 3.26B 2.97B 5.57B 381B 5.58B 39.09B 15.07B 194B 14.93B 14.6B 626B 26.03B 3.99B 3.48B 3.28B 2.99B 5.6B 383B 5.61B 39.28B 15.14B 195B 15B 14.67B 629B
Net income 4.59B 703M 613M 578M 526M 986M 67.39B 988M 6.92B 2.67B 34.33B 2.64B 2.58B 111B 4.6B 706M 616M 580M 528M 990M 67.67B 992M 6.95B 2.68B 34.47B 2.65B 2.59B 111B
Net Debt 4B 614M 535M 504M 459M 861M 58.83B 862M 6.04B 2.33B 29.97B 2.31B 2.26B 96.71B -182M -27.89M -24.32M -22.9M -20.86M -39.11M -2.67B -39.16M -274M -106M -1.36B -105M -102M -4.39B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change
18/09/26 EUR 5.695 -0.18%
17/09/26 EUR 5.705 +1.97%
16/09/26 EUR 5.595 +0.27%
15/09/26 EUR 5.580 -6.84%
14/09/26 EUR 5.990 +0.59%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
42.56DKK
Average target price
49.12DKK
Spread / Average Target
+15.40%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!